Should I Buy DBD? DBD 2026 Analysis

Should You Buy Diebold Nixdorf Inc (DBD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

69.010

1 Day change

-0.49%

52 Week Range

72.530

Analysis Updated At

2026/01/29

Diebold Nixdorf Inc (DBD) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company shows some positive trends like hedge fund interest and slightly improved revenue, the negative financial performance, insider selling, and lack of strong technical or proprietary trading signals suggest a cautious approach. Holding off until after the upcoming earnings release on February 12, 2026, may provide better clarity on the company's trajectory.

Technical Analysis

The stock's MACD is negative and expanding downward, indicating bearish momentum. RSI is neutral at 50.883, showing no clear signal. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading near its pivot point (69.699) with resistance at 71.834 and support at 67.563. Overall, the technical indicators are mixed.

Options Data

Bearish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Hedge funds are significantly increasing their positions, with a 200.38% increase in buying over the last quarter. The company is set to release its Q4 and full-year 2025 financial results on February 12, 2026, which could provide clarity on its performance.

Neutral/Negative Catalysts

Insiders are selling heavily, with a 113.75% increase in selling activity over the last month. The company's financial performance in Q3 2025 showed a significant drop in net income (-283.48% YoY) and EPS (-285.00% YoY). The stock has a 50% chance of declining further (-1.28% in the next day, -2.54% in the next week, -4.37% in the next month).

Financial Performance

In Q3 2025, revenue increased by 1.95% YoY to $945.2M, but net income dropped by -283.48% YoY to $41.1M, and EPS fell by -285.00% YoY to 1.11. Gross margin improved slightly to 26.23%, up 0.58% YoY. The financial performance indicates weak profitability despite marginal revenue growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data is available for this stock at the moment.

2 Analyst Rating

Wall Street analysts forecast DBD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DBD is 80 USD with a low forecast of 80 USD and a high forecast of 80 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 69.350

Low

Averages

High

Current: 69.350

Low

Averages

High

Wedbush

Antoine Legault

Outperform

maintain

$60 -> $70

AI Analysis

2025-08-07

Reason

Wedbush

Antoine Legault

Price Target

$60 -> $70

AI Analysis

2025-08-07

maintain

Outperform

Reason

Wedbush analyst Antoine Legault raised the firm's price target on Diebold to $70 from $60 and keeps an Outperform rating on the shares. In the firm's view, the better Q2 results combined with effective tariff mitigation and LEAN initiatives, a strong backlog, and good visibility into forward revenues all lend further credence to management's decision to not only maintain its guide, but to narrow the range towards the high end of its prior full year outlook.

Wedbush

Antoine Legault

Outperform

initiated

$60

2025-07-22

Reason

Wedbush

Antoine Legault

Price Target

$60

2025-07-22

initiated

Outperform

Reason

Wedbush assumed Antoine Legault initiated coverage of Diebold with an Outperform rating and $60 price target. Heading into Q2 earnings, the firm believes that backlog and cash flow figures will be in focus, as well as any potential impacts from a weaker USD, changing tariff policies, and order pull-ins. Wedbush will also look for further management commentary and updates around signs pointing to uptick in orders driven by the beginning of a refresh cycle, and progression or shifts to a services model and/or increased software traction and value-add.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DBD

Unlock Now

DBD Should I Buy

DBD Should I Buy

Should You Buy Diebold Nixdorf Inc (DBD) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch